Evidence map›Paper›PMID 41399628›Full record

ArticleContemporary clinical trials communications2025

A protocol for a randomized controlled trial of photobiomodulation for management of temporomandibular disorder pain in Adults.

Selenia Rubio, Patricia Cabrera, Rory Reever, Cesar Migliorati, Richard Ohrbach, Frank C Gibson, Zhigang Li, Angela Mickle, Rosalynn R Z Conic, Roger B Fillingim and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05916235 (Photobiomodulation for Management of Temporomandibular Disorder Pain), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05916235 narecruitingnot on this map

Photobiomodulation for Management of Temporomandibular Disorder Pain

TypeinterventionalSponsorUniversity of FloridaRan2024 to 2028Enrolled130ConditionsPain Related to TMDArmsTHOR® laser system
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Selenia RubioDepartment of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, 32610, USA.
Patricia CabreraDepartment of Prosthodontics, University of Florida, Gainesville, FL, 32610, USA.
Rory ReeverDepartment of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, 32610, USA.
Cesar MiglioratiDepartment of Oral and Maxillofacial Diagnostic Sciences, University of Florida, Gainesville, FL, 32610, USA.
Richard OhrbachSUNNY School of Medicine, University at Buffalo, Buffalo, NY, 14214, USA.
Frank C GibsonDepartment of Oral Biology, University of Florida, Gainesville, FL, 32610, USA.
Zhigang LiDepartment of Biostatistics, University of Florida, Gainesville, FL, 32610, USA.
Angela MickleDepartment of Physical Medicine and Rehabilitation, University of Florida, Gainesville, FL, 32610, USA.
Rosalynn R Z ConicDepartment of Physical Medicine and Rehabilitation, University of Florida, Gainesville, FL, 32610, USA.
Roger B FillingimDepartment of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, 32610, USA.
Margarete Ribeiro DasilvaDepartment of Prosthodontics, University of Florida, Gainesville, FL, 32610, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence-based treatments for painful temporomandibular disorders (TMD) are lacking. The most common treatments for painful TMDs, intraoral appliances and pain medication, provide suboptimal pain control, often leading to treatment-limiting adverse effects. Photobiomodulation therapy (PBM) shows substantial potential for the management of pain in people with a TMD; however, its efficacy for TMD pain reduction has not been rigorously tested. We will conduct a double-blind, randomized, placebo-controlled clinical trial of multimodal PBM for TMD pain. This single-site trial will randomize 130 participants, aged 18 years and older, with chronic painful TMD. Individuals will complete a detailed medical history to confirm eligibility criteria, followed by a clinical exam to confirm TMD case status according to the Diagnostic Criteria for TMD (DC/TMD). Eligible participants will be randomized to either active or sham PBM treatment. Participants will complete eight treatment visits scheduled 2-5 days apart. This will be followed by a post-intervention visit that will include symptom questionnaires, TMD exam, pressure pain threshold (PPT) measures, and blood draw. A 6-month follow-up visit will include a TMD exam, questionnaires, and pressure pain threshold measures. Analyses will determine intervention effects on the primary outcome (pain intensity) and multiple secondary outcomes and will examine whether changes in inflammation and pain sensitivity are associated with the intervention response. Clinicaltrialsgov identifier: NCT05916235.

Indexed as

Joint diseasesMusculoskeletal diseasesMyofascial pain syndromesPhotobiomodulation (PBM)Temporomandibular disorders (TMD)

Identifiers

PMID41399628
PMCPMC12702193

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.